Orenco Systems Inc.

John Nicoli has more than thirty-five years of experience in the mechanical contracting and capital planning fields. He has participated in 900+ facility assessments across the country, as project leader or mechanical engineer. He also serves as OSI's treasurer and chief financial officer. Mr. Nicoli successfully spearheaded the evaluation of an 30 property affordable housing acquisition in Washington for Mercy Housing and has participated in major housing authority portfolio efforts from Philadelphia to Lincoln, NE. He has had a major role in portfolio assessments for the Michigan State Housing Development Authority, Volunteers of America and The Salvation Army efforts. Mr. Nicoli is a specialist in the heating, ventilating and air conditioning (HVAC) fields. He has managed an HVAC control business, responsible for mechanical installations, negotiating and supervising subcontracts and directing field staff.

Mr. Leung is currently President of OSI Oncology at OSI Pharmaceuticals, a leading biotechnology company based in Melville, NY. The mission of OSI Oncology is to shape medicine and change lives by discovering, developing and commercializing novel, molecular-targeted therapy for treating cancer. Mr. Leung leads the entire oncology business unit, including Research, Development, Medical Affairs, Sales and Marketing. Prior to joining OSI, Mr. Leung was Group VP, Global Prescription Business at Pharmacia and was a member of the CEO’s Operating Committee. He headed up Pharmacia’s Oncology Franchise with business and medical affairs operations in over 80 countries. Mr. Leung also oversaw all the oncology R&D projects and portfolio strategies as the co-chair of the Oncology Development Committee. During his 4-year tenure at Pharmacia, which ended with the acquisition by Pfizer, he doubled the size of the oncology business to $1.3 billion in revenues, building it into one of the then largest oncology therapeutic companies in the world. He orchestrated two new product launches and helped build one of the strongest oncology pipeline in the industry through acquisition and in-licensing. Mr. Leung began his career in the pharmaceutical industry at Eastman Pharmaceuticals/Sterling Drug Inc., a division of Eastman Kodak Company, where he gained worldwide business development experience. He then had a distinguished career at Bristol-Myers Squibb where he launched and led the growth of multiple pharmaceutical products in oncology and a variety of primary care and specialty therapeutic areas. Mr. Leung is a pharmacist, trained at the University of Texas at Austin where he earned his pharmacy degree with High Honors. Following some years of practice in the hospital environment, Mr. Leung earned his M.S. degree at the University of Wisconsin-Madison with concentration in pharmaceutical marketing. As a member of the National Cancer Institute Clinical Trial Advisory Committee (NCI CTAC), Mr. Leung serves as an advisor to the NCI Director. He is an active member and a member of the Nominating Committee of C-Change (www.cchangetogether.org), a national initiative chaired by former President George Bush and Mrs. Barbara Bush with the goal of reducing cancer mortality and incidence in the United States. Also, he is the founding chairman of the Life Sciences Consortium, a new initiative of the CEO Roundtable on Cancer (www.ceoroundtableoncancer.org). In this role, he leads an industry-wide effort to facilitate cross-company and cross-sector collaboration and to help expedite oncology drug discovery and development. Mr. Leung is a distinguished speaker on healthcare/industry issues and has lectured at major universities.